| scholarly article | Q13442814 |
| P50 | author | Nagadenahalli Byrareddy Siddappa | Q45630014 |
| Jagannadha Sastry | Q58305544 | ||
| P2093 | author name string | Michael A Barry | |
| Guojun Yang | |||
| Shailbala Singh | |||
| P2860 | cites work | Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP | Q21090975 |
| Alum adjuvant: some of the tricks of the oldest adjuvant | Q37969028 | ||
| Vaccines against mucosal infections | Q38009608 | ||
| Recent progress in mucosal vaccine development: potential and limitations | Q38029250 | ||
| Optimizing efficacy of mucosal vaccines. | Q38059754 | ||
| Dendritic cells of the oral mucosa | Q38113759 | ||
| Immunomodulatory properties of the vaccine adjuvant alum | Q38181867 | ||
| Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 | ||
| Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. | Q39886289 | ||
| Cytotoxic T-cell memory without antigen | Q41460535 | ||
| Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. | Q44498591 | ||
| CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination | Q47765446 | ||
| Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells. | Q51890963 | ||
| Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues | Q79869367 | ||
| Sublingual immunization induces broad-based systemic and mucosal immune responses in mice | Q81587050 | ||
| Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes | Q22241377 | ||
| Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection | Q27332360 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. | Q30342455 | ||
| Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. | Q30374900 | ||
| Global trends in molecular epidemiology of HIV-1 during 2000-2007. | Q30399382 | ||
| Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza | Q30410241 | ||
| Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. | Q31153121 | ||
| Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection | Q33382060 | ||
| Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing | Q33392865 | ||
| R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models | Q33640144 | ||
| Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection | Q34287659 | ||
| Mucosal immunity and vaccines | Q34409172 | ||
| Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens | Q34438489 | ||
| Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice | Q34524955 | ||
| Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses | Q34675592 | ||
| Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges | Q35134733 | ||
| CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections | Q35713871 | ||
| Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis | Q35774679 | ||
| Functional roles of NKT cell in the immune system | Q35883229 | ||
| Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials | Q36083337 | ||
| Mucosal vaccines: the promise and the challenge | Q36402244 | ||
| HIV transmission | Q36526615 | ||
| Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. | Q36598607 | ||
| Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus | Q36674033 | ||
| Mucosal vaccine adjuvants update | Q36758075 | ||
| Harnessing invariant NKT cells in vaccination strategies | Q37349692 | ||
| Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity | Q37552013 | ||
| Immunogenicity of HIV-1 envelope glycoprotein oligomers | Q37667740 | ||
| Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer | Q37692880 | ||
| Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. | Q37785949 | ||
| Sublingual mucosa: A new vaccination route for systemic and mucosal immunity | Q37829073 | ||
| Sublingual vaccination | Q37832086 | ||
| Defending the mucosa: adjuvant and carrier formulations for mucosal immunity | Q37867814 | ||
| P433 | issue | 51 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 6934-6940 | |
| P577 | publication date | 2014-11-02 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein | |
| P478 | volume | 32 |
| Q52607682 | Alpha-galactosylceramide (αGalCer) Enhances Vaccine-induced Protection in a Model of Ricin Intoxication. |
| Q38863128 | Exploring new packaging and delivery options for the immunization supply chain. |
| Q89552900 | Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope |
| Q36289461 | Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi |
| Q36735275 | Intranasal Vaccination Affords Localization and Persistence of Antigen-Specific CD8⁺ T Lymphocytes in the Female Reproductive Tract. |
| Q38727453 | Mucosal vaccine delivery: Current state and a pediatric perspective |
| Q37677278 | Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles |
| Q50531631 | The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens. |
| Q89074520 | The interaction between invariant Natural Killer T cells and the mucosal microbiota |
Search more.